NSCLC — Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC
Citation(s)
A Phase I/II Study of Anlotinib Combined With Platinum-based Chemotherapy as the First-line Treatment of Patients With Locally Advanced or Advanced Non-Small Cell Lung Cancer